Literature DB >> 19714314

Tacrolimus differentially regulates the proliferation of conventional and regulatory CD4(+) T cells.

Kazue Kogina1, Hirofumi Shoda, Yumi Yamaguchi, Nelson H Tsuno, Koki Takahashi, Keishi Fujio, Kazuhiko Yamamoto.   

Abstract

Tacrolimus is a widely used T cell targeted immunosuppressive drug, known as a calcineurin inhibitor. However, the exact pharmacological effects of tacrolimus on CD4(+) T cells have yet to be elucidated. This study investigated the effects of tacrolimus on CD4(+) T cell subsets. Mouse or human CD4(+) T cells were cultured with immobilized anti-CD3/CD28 antibodies in the presence of tacrolimus. The cell division of CD4(+) T cells was analyzed using a flow cytometer according to the expression of Foxp3. The gene expression patterns of tacrolimus-exposed T cells were examined by quantitative PCR. In the case of conventional CD4(+) T cells (Tconv cells), tacrolimus inhibited T cell receptor stimulation-induced cell division. In contrast, the cell division of regulatory CD4(+) T cells (Treg cells) was even promoted in the presence of tacrolimus, especially in humans. Tacrolimus did not promote conversion of Tconv to Treg cells in mice. Furthermore, tacrolimus modified the expression levels of Foxp3-regulated T cell receptor signal related-genes, PTPN22 and Itk, in human Treg cells. Immunosuppressive effect of tacrolimus may be attributed to the relatively enhanced proliferation of Treg cells in association with altered gene expression levels of TCR signaling molecules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19714314     DOI: 10.1007/s10059-009-0114-z

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  9 in total

1.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

2.  Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial.

Authors:  Ivan Kristo; Julia Wilflingseder; Alexander Kainz; Julian Marschalek; Thomas Wekerle; Ferdinand Mühlbacher; Rainer Oberbauer; Martin Bodingbauer
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

3.  A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.

Authors:  Tulio B Abud; Francisco Amparo; Ujwala S Saboo; Antonio Di Zazzo; Thomas H Dohlman; Joseph B Ciolino; Pedram Hamrah; Reza Dana
Journal:  Ophthalmology       Date:  2016-04-13       Impact factor: 12.079

4.  Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients.

Authors:  Manisha Patel; Martha Stefanidou; Caroline B Long; Melissa J Fazzari; Lydia Tesfa; Marcela Del Rio; Jacqueline Lamour; Rosanna Ricafort; Rebecca P Madan; Betsy C Herold
Journal:  Pediatr Transplant       Date:  2011-07-18

5.  Study Design: Human Leukocyte Antigen Class I Molecule A02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation.

Authors:  Katharina Schreeb; Emily Culme-Seymour; Essra Ridha; Céline Dumont; Gillian Atkinson; Ben Hsu; Petra Reinke
Journal:  Kidney Int Rep       Date:  2022-04-06

6.  Individualized Immunosuppressive Protocol of Liver Transplant Recipient Should be Made Based on Splenic Function Status.

Authors:  Ji-Yong Song; Guo-Sheng Du; Li Xiao; Wen Chen; Long-Long Suo; Yu Gao; Li-Kui Feng; Bing-Yi Shi
Journal:  Chin Med J (Engl)       Date:  2016-06-05       Impact factor: 2.628

Review 7.  Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases.

Authors:  Jae-Ung Lee; Li-Kyung Kim; Je-Min Choi
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

8.  Low-dose oral cholecalciferol is associated with higher numbers of Helios(+) and total Tregs than oral calcitriol in renal allograft recipients: an observational study.

Authors:  Mostafa G Aly; Karina Trojan; Rolf Weimer; Christian Morath; Gerhard Opelz; Mohammed A Tohamy; Volker Daniel
Journal:  BMC Pharmacol Toxicol       Date:  2016-06-14       Impact factor: 2.483

9.  Tolerogenic β2-glycoprotein I DNA vaccine and FK506 as an adjuvant attenuates experimental obstetric antiphospholipid syndrome.

Authors:  Ya-Hsuan Chao; Der-Yuan Chen; Joung-Liang Lan; Kuo-Tung Tang; Chi-Chien Lin
Journal:  PLoS One       Date:  2018-06-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.